Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
The present invention provides a medicine containing a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.
1. A method for treating cancer in a patient, comprising administering to the patient
Poly I:C or a salt thereof;
a fusion protein of lymphocyte activation gene 3 (LAG-3) protein and IgG; and
at least one cancer-antigen derived peptide.
2. The method according to claim 1 , wherein two or more cancer-antigen derived peptides are administered.
3. A method for inducing a specific immune response to a cancer cell in a patient in need thereof, comprising administering to the patient
Poly I:C or a salt thereof;
a fusion protein of lymphocyte activation gene 3 (LAG-3) protein and IgG; and
at least one cancer-antigen derived peptide; and wherein said specific immune response is (i) CD4+ and/or CD8+ T-cell proliferation, (ii) interferon-gamma, GM-CSF, interleukin-4 (IL-4), IL-5, and/or IL-17A production, (iii) CD4+ and/or CD8+ T-cell infiltration in tumor tissue, and/or (iv) PD-1, LAG-3, and/or TIGIT downregulation in CD4+ and CD8+ T-cells.
4. The method according to claim 3 , wherein two or more cancer-antigen derived peptides are administered.
5. The method of claim 3 , wherein said specific immune response is CD4+ and/or CD8+ T-cell proliferation.
6. The method of claim 3 , wherein said specific immune response is interferon-gamma, GM-CSF, IL-4, IL-5, and/or IL-17A production.
7. The method of claim 3 , wherein said specific immune response is CD4+ and/or CD8+ T-cell infiltration in tumor tissue.
8. The method of claim 3 , wherein said specific immune response is PD-1, LAG-3, and/or TIGIT downregulation in CD4+ and CD8+ T-cells.